Clinical trial
A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma.
NCT00601003 is registered in ClinicalTrials.gov with Giselle Sholler as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma.
- Lead sponsor
- Giselle Sholler
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 14, 2008
- Completion date
- October 28, 2022
- Enrollment
- 112 (actual)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.